JW Pharmaceutical said it has launched a compound digestive medicine, Besticon, and begun marketing activities in earnest.
Besticon is a compound digestive medicine composed of alverine citrate, an antispasmodic agent, and simethicone, a degassing agent. It is effective on functional indigestion and irritable bowel syndrome, such as the antispasmodics of the gastrointestinal tract. According to JW, it also works well in removing intestinal gases and abdominal pain caused by abdominal distention.
The company held a symposium for domestic health and medical experts last month, sharing the latest knowledge of functional dyspepsia or indigestion treatment and gastroesophageal reflux disease treatment with the introduction of Besticon.
Hwang Hee-jin, a Catholic Kwandong University International St. Mary's Hospital professor, made an opening presentation. Oh Bum-jo, a Seoul National University Boramae Medical Center professor, and Lee Jun-hyung, a professor at Inje University Ilsan Paik Hospital, released their research results for the workshop.
"Besticon can be used in combination with attack factor inhibitors, defense factor enhancers, symptom enhancers, antacid drugs, and non-benefit digestive drugs for the treatment of digestive diseases," Professor Oh said.
A JW official said, "Besticon is a product that can be combined with other digestive medicines and can greatly increase the satisfaction of patients with digestive disorders.
The official added that the company would continue expanding its role in the digestive market based on its diverse lineup of digestive solvents.